Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. Statistics
Share Statistics
Roivant Sciences Ltd. has 713.55M shares outstanding. The number of shares has increased by -3.41% in one year.
Shares Outstanding | 713.55M |
Shares Change (YoY) | -3.41% |
Shares Change (QoQ) | -1.98% |
Owned by Institutions (%) | 77.82% |
Shares Floating | 438.67M |
Failed to Deliver (FTD) Shares | 1.72K |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 44.88M, so 6.17% of the outstanding shares have been sold short.
Short Interest | 44.88M |
Short % of Shares Out | 6.17% |
Short % of Float | 10.01% |
Short Ratio (days to cover) | 8.38 |
Valuation Ratios
The PE ratio is 1.88 and the forward PE ratio is -11.28. Roivant Sciences Ltd.'s PEG ratio is 0.
PE Ratio | 1.88 |
Forward PE | -11.28 |
PS Ratio | 65.46 |
Forward PS | 3.5 |
PB Ratio | 1.37 |
P/FCF Ratio | -10.66 |
PEG Ratio | 0 |
Enterprise Valuation
Roivant Sciences Ltd. has an Enterprise Value (EV) of 2.13B.
EV / Sales | 17.09 |
EV / EBITDA | 0.49 |
EV / EBIT | -2.79 |
EV / FCF | -2.78 |
Financial Position
The company has a current ratio of 25.24, with a Debt / Equity ratio of 0.08.
Current Ratio | 25.24 |
Quick Ratio | 25.1 |
Debt / Equity | 0.08 |
Debt / EBITDA | 0.12 |
Debt / FCF | -0.65 |
Interest Coverage | 121.97 |
Financial Efficiency
Return on Equity is 72.86% and Return on Invested Capital is 60.48%.
Return on Equity | 72.86% |
Return on Assets | 60.21% |
Return on Invested Capital | 60.48% |
Revenue Per Employee | $137.44K |
Profits Per Employee | $4.79M |
Employee Count | 908 |
Asset Turnover | 0.02 |
Inventory Turnover | 0.79 |
Taxes
Income Tax | 22.22M |
Effective Tax Rate | 0.52% |
Stock Price Statistics
The stock price has increased by -9.8% in the last 52 weeks. The beta is 1.26, so Roivant Sciences Ltd.'s price volatility has been higher than the market average.
Beta | 1.26 |
52-Week Price Change | -9.8% |
50-Day Moving Average | 10.71 |
200-Day Moving Average | 11.31 |
Relative Strength Index (RSI) | 32.45 |
Average Volume (20 Days) | 5.26M |
Income Statement
In the last 12 months, Roivant Sciences Ltd. had revenue of 124.8M and earned 4.35B in profits. Earnings per share was 5.55.
Revenue | 124.8M |
Gross Profit | 96.83M |
Operating Income | 4.24B |
Net Income | 4.35B |
EBITDA | 4.31B |
EBIT | 4.29B |
Earnings Per Share (EPS) | 5.55 |
Balance Sheet
The company has 6.54B in cash and 499.75M in debt, giving a net cash position of 6.04B.
Cash & Cash Equivalents | 6.54B |
Total Debt | 499.75M |
Net Cash | 6.04B |
Retained Earnings | 576.17M |
Total Assets | 5.79B |
Working Capital | 5.22B |
Cash Flow
In the last 12 months, operating cash flow was -765.27M and capital expenditures -1.38M, giving a free cash flow of -766.65M.
Operating Cash Flow | -765.27M |
Capital Expenditures | -1.38M |
Free Cash Flow | -766.65M |
FCF Per Share | -0.98 |
Margins
Gross margin is 77.59%, with operating and profit margins of 3399.19% and 3484.86%.
Gross Margin | 77.59% |
Operating Margin | 3399.19% |
Pretax Margin | 3408.33% |
Profit Margin | 3484.86% |
EBITDA Margin | 3453.86% |
EBIT Margin | 3399.19% |
FCF Margin | -614.33% |
Dividends & Yields
ROIV does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 53.24% |
FCF Yield | -9.38% |
Analyst Forecast
The average price target for ROIV is $18, which is 82.7% higher than the current price. The consensus rating is "Buy".
Price Target | $18 |
Price Target Difference | 82.7% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Scores
Altman Z-Score | 20.18 |
Piotroski F-Score | 4 |